Avis Budget Group Q2 Earnings, Revenue Fall-February 2024-www.financetom.com

Avis Budget Group Q2 Earnings, Revenue Fall

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Avis Budget Group Q2 Earnings, Revenue Fall

Aug 5, 2024 2:38 PM

05:17 PM EDT, 08/05/2024 (MT Newswires) -- Avis Budget Group ( CAR ) reported Q2 earnings Monday of $0.41 per share, down from $11.01 a year earlier.

Analysts surveyed by Capital IQ expected $2.45.

Revenue for the quarter ended June 30 was $3.05 billion, falling from $3.12 billion a year ago.

Analysts polled by Capital IQ expected $3.14 billion.

Price: 81.48, Change: -2.48, Percent Change: -2.95

Previous page： Yen slumps after Japan's election, dollar set for biggest monthly rise in 2-1/2 years Next page： Eli Lilly gets nod to launch weight-loss drug in Hong Kong - Bloomberg News

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Yen slumps after Japan's election, dollar set for biggest monthly rise in 2-1/2 years

Nov 3, 2024

SINGAPORE (Reuters) -The yen sank to a 3-month low on Monday as investors figured the loss of a parliamentary majority for Japan's ruling coalition in weekend elections would slow interest rate rises, while the U.S. dollar headed for its biggest monthly gain since April 2022. In the Asia session, the yen weakened as far as 153.88 per dollar and 166.06...

Eli Lilly gets nod to launch weight-loss drug in Hong Kong - Bloomberg News

Nov 3, 2024

Oct 27 (Reuters) - Eli Lilly ( LLY ) expects to start selling its weight-loss drug in Hong Kong as early as the end of this year, Bloomberg News reported on Sunday. The company has received the Hong Kong government approval to sell its tirzepatide injections - branded as Mounjaro - in a device called Kwikpen for both long-term weight...

LENZ Therapeutics, Corxel Pharmaceuticals Say Vision Decline Treatment Met Primary Phase 3 Endpoint

Nov 3, 2024

04:35 AM EDT, 10/28/2024 (MT Newswires) -- LENZ Therapeutics ( LENZ ) and Corxel Pharmaceuticals on Sunday reported positive topline data from a phase 3 clinical trial in China of LNZ100 in patients with presbyopia, a condition that results in a progressively worsening ability to see nearby objects clearly. The companies said the study met its primary endpoint, with 74%...

Elbit Systems Wins $200 Million Laser System Supply Contract From Israel

Nov 3, 2024

04:41 AM EDT, 10/28/2024 (MT Newswires) -- Elbit Systems ( ESLT ) said Monday it won a contract worth $200 million from the Israeli Ministry of Defense to supply high-power laser systems. The contract calls for the delivery of laser systems for the country's Iron Beam air defense project and includes ongoing support services, the company said. Price: 212.85, Change:...